China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
Ascentage Pharma
Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches
Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) reported 2025 financial results, with revenue declining...
Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates – APG‑115 and HSK42360 Target High‑Unmet‑Need Childhood Cancers
China’s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support...
Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China’s National Medical Products Administration...
Ascentage’s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies
Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA)...
Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting
China‑based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines—olverembatinib (HQP1351), a first‑in‑China...
InxMed Secures HK$100 M Private Placement from TruMed Health
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has...
Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales
China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...
Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial
Ascentage Pharma Group International (HKG: 6855) announced that it has received clearance from the U.S....
Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation...
Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that it has received conditional marketing approval...
Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...
Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...
Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment
China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor
Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575),...
Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations
The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...
Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...